Faxen mit Vaxgen!

Dem amerikanischen Hersteller von Flüssigmedikamenten (US- Ticker VXGN) winken angelsächsische Vermarktungs- und Lizenzrechte!

Is heute wahrscheinlich die US- Aktie des Tages!

Gr.Gr.

UPDATE - Dendreon gets fast track on prostate cancer drug
Thursday September 4, 8:19 am ET

(Adds details paragraphs 2-3, 5-6)

NEW YORK, Sept 4 (Reuters) - Biotechnology company Dendreon Corp. (NasdaqNM:DNDN - News) on Thursday said U.S. regulators would speed their review of the company's prostate cancer drug Provenge, currently in late-stage testing.

Shares of the company jumped to $7.70 in pre-market trading on Instinet from a closing price of $6.23 on Wednesday.

The U.S. Food and Drug Adminstration's "fast-track" designation means the agency will review data from clinical trials before all the company's data has been submitted. The fast-track status often leads to a "priority," or six-month, review of a drug, compared to the normal 12-month review.

Dendreon in June won another concession from the FDA when the agency ruled the company could exclude prostate cancer patients with the most aggressive tumors from its pivotal Phase III trial.

Previous clinical trials suggested the drug delays progression of the disease and reduces pain from the cancer. Dendreon has previously said it hopes to have Provenge on the market in 2005.

The treatment consists of immune-system cells called "dendrites" that are taken from the body and exposed to a genetically engineered protein, or antigen, found only on prostate cancer cells. They are then re-infused in the body with the task of triggering its immune system to fight foreign invaders such as cancer cells.

 

Hey Gruenspan,liest und interessiert ja eh niemanden,aber auch DNDN sollte heute mit den News für Performance sorgen.Habe sie bei Eski im Depot(nicht privat).

Stimmt, so isses!
Da haste ja mit DNDN nen` möglichen Treffer gelandet.

Ich wünsch Dir watt!

                          Gr.Gr.

freuen wir uns VXGN aktuell 25%; DNDN 40%.

Tja DNDN hatte ich schon lange auf dem Kieker.Ist ein Superwert.Im Tradingsinne wahrscheinlich erst 2004ff voll im Geld.Schau Dir mal das Marktpotenzial an.Das Krebsmittel (Prostata)hat etwa 3.0 MRD Umsatzchancen.Andere Patente sind in der Pipeline.Über 3.00 Dollar Cash.Ich will ja nicht spinnen,aber wenn ich so an IMCL denke,könnten nächstes Jahr oder 2005 Kurse um 100;-- realistisch sein.

Ciao B.L.

Da is was gegen Kursschwäche und AIDS in Arbeit.


       
     

`(*_*)´